One of the major challenges in pancreatic cancer research is the availability of clinical samples from patients undergoing surgical resection with complete demographic and clinico-pathological information. In our ongoing efforts, we have been successful in establishing multiple cohorts of resected pancreatic cancer samples from cases in the United States and abroad. This includes a new approved study protocol to collect tumors and/or blood samples from 500 PDAC cases in the greater Baltimore area with myself as principal investigator. This collection will be an invaluable asset for our pancreatic cancer program. The results from our pilot gene-expression profiling study showed that a lower expression of DPEP1 (dipeptidase 1) in tumors was associated with poorer survival in two independent cohorts of PDAC and was independent of stage and resection margin status (Zhang et. al., PLoS One, 2012). DPEP1 expression was significantly lower in tumors as compared to adjacent non-tumor pancreas from the same patient in both the cohorts. Overexpression of DPEP1 in pancreatic cancer cell lines inhibited cell migration and invasion, and increased the sensitivity to gemcitabine, a first-line drug for treating pancreatic cancer. We also showed that DPEP1 is regulated by EGF/MEK/MAPK pathway, and MEK1/2 inhibitor enhanced DPEP1 expression in vitro. In view of these findings, we propose that re-expression of DPEP1 by novel approaches could be useful for the treatment of PDAC in improving patient survival. Currently, we are testing the hypothesis that DPEP1 inhibits tumor progression in vivo. In our continuing effort of examining the tumor biology associated with disease aggressiveness, we are currently comparing the gene expression profile of tumors in two groups of resected patients: one with a short survival (<7 months) and the other with a longer survival (24-70 months) following resection, and further testing the hypotheses that a) Inflammatory genes drive tumor aggressiveness in resected patients and b) Inflammation-associated gene signature defines aggressive subtypes in resectable PDAC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011162-04
Application #
8553012
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2012
Total Cost
$609,814
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code